BCL 6 enables Ph 1 acute lymphoblastic leukaemia cells to survive BCR – ABL 1 kinase inhibition

@inproceedings{Duy2011BCL6E,
  title={BCL 6 enables Ph 1 acute lymphoblastic leukaemia cells to survive BCR – ABL 1 kinase inhibition},
  author={C. Vu Duy and Christian Hurtz and Seyedmehdi Shojaee and Leandro Carlos Cerchietti and Huimin Geng and Srividya Swaminathan and Lars Klemm and Soo-miKweon and Rahul Nahar and Melanie Braig and Eugene Park and Yong-mi Kim and Wolf-Karsten Hofmann and Sebastian Herzog and Hassan Jumaa and H Phillip Koeffler and J. Jessica Yu and Nora Heisterkamp and Thomas G Graeber and Hong Wu and B Hilda Ye and Ari Melnick and Markus M{\"u}schen},
  year={2011}
}
Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR–ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases. However, even effective TKIs typically fail to eradicate leukaemia-initiating cells (LICs), which often cause recurrence of leukaemia after initially successful treatment. Here we report the discovery of a novel mechanism of drug resistance, which… CONTINUE READING